TB-500 Dosage: What Research Has and Hasn't Tested

Is there a proven TB-500 dosage?

No published study has tested a TB-500 dosage in people. FDA wrote an evaluation dated May 15, 2026, for its July 2026 compounding advisory committee meeting. Compounding means pharmacies custom-making drugs. In it, FDA found no clinical studies or human exposure data for TB-500 by any route. So FDA says its safety risks in humans are unknown.

TB-500 is a lab-made chain of seven amino acids, the building blocks of proteins. It copies amino acids 17 to 23 of thymosin beta-4 (Tβ4), a natural repair protein. It also has an acetyl group, a small chemical cap, at the front. That is how FDA's 2026 TB-500 briefing document describes it. FDA also says that thymosin beta-4 and TB-500 are not the same substance. So a Tβ4 result does not carry over to TB-500. A 2005 review calls Tβ4 the major actin-sequestering molecule in eukaryotic cells (Goldstein et al., 2005). That means it holds actin in reserve in cells with a nucleus, like ours. Actin is the protein that forms a cell's inner skeleton. FDA also notes that TB-500 is not part of any FDA-approved drug.

Dosing schedules for TB-500 circulate online. We found no primary source for any of them. We checked FDA's review, the human trials and PubMed, a database of medical research papers. Claims about hair are covered on our TB-500 hair growth page.

This content is for educational purposes only and is not medical advice. Several seller websites FDA reviewed label these products for research use only. A qualified clinician can advise on any health decision.

Where do TB-500 dosage numbers come from?

The only TB-500 doses given to animals in FDA's review come from studies of how the body processes it. None tested whether it heals anything.

In the horses, blood levels of TB-500 peaked 60 to 120 minutes after the shot. They could no longer be measured 6 to 10 hours after it, FDA reports. A vial size is not a dose. None of these numbers is tied to a safe or useful dose in people.

FDA found no formal toxicity studies of TB-500. It found no single-dose, repeat-dose, gene damage, reproductive or cancer studies. So no such data sets a safe upper limit either.

What doses were tested for thymosin beta-4 in people?

Two small Phase I safety trials, the earliest stage of testing in people, gave thymosin beta-4 to healthy volunteers, by injection into a vein. One used synthetic Tβ4. The other used NL005, a recombinant version with 44 amino acids. Recombinant means it was made using genetic engineering. Neither trial tested TB-500. Neither tested healing.

• Synthetic Tβ4: There were four groups of 10 people. Each person got one dose of 42, 140, 420 or 1,260 mg, or a placebo (a dummy). They then got the same dose daily for 14 days. Health problems during the trial were few, and mild or moderate. There were no dose-limiting toxicities, meaning harms bad enough to stop the dose going up. There were no serious adverse events, meaning serious health problems, either (Ruff et al., 2010).
• Recombinant human Tβ4 (NL005), China: 54 people got one dose of 0.05 to 25 micrograms per kg, or a placebo. Another 30 got 0.5, 2 or 5 micrograms per kg, or a placebo, once a day for 10 days. Health problems during the trial were mild to moderate. There were no dose-limiting toxicities or serious adverse events. Repeat doses showed no obvious build-up (Wang et al., 2021).

Both trials were run with heart attack treatment in mind. Their doses describe a different molecule, given by a different route. They do not show that any amount of TB-500 under the skin is safe.

Thymosin beta-4 has also been tested on the skin and eye. A Phase 2 trial is a mid-sized test in patients. One such trial, in 73 people with venous leg ulcers, tested thymosin beta-4 applied to the wound, at several strengths (Guarnera et al., 2010). Venous leg ulcers are sores caused by poor blood flow in the veins. A Phase 2 dry-eye trial gave nine people either 0.1% Tβ4 eye drops or a dummy (vehicle). They used the drops six times a day for 28 days (Sosne et al., 2015). None of these tested TB-500.

Is there a TB-500 dosage calculator?

Yes, but only as a unit converter.

The site's TB-500 calculator turns a vial size, the water added and a dose you enter into syringe units. It pre-fills no dose, because no study has set one for people.

The mixing maths is simple. The strength equals the milligrams in the vial divided by the millilitres of water added. The powder does not change; only the strength per millilitre does.

Is there a TB-500 dosage for a BPC-157 blend?

No primary source gives a TB-500 dosage for a BPC-157 blend. FDA found no study that gave TB-500 to people at all. FDA also searched its food and supplement complaint system. It found two reports about blended TB-500 and BPC-157, with no safety assessment. We found no published trial of a pre-mixed vial of the two, at any strength.

So a blend dosage chart or per-day figure has no study behind it. A label that gives only a combined total does not say how much of each peptide is inside. The BPC-157 vs TB-500 comparison sets out what the record shows for each peptide on its own.

What does the TB-500 tendon healing evidence show?

No published study has tested TB-500 on a tendon in people. FDA found no human data for it at all. It also found no animal study of whether TB-500 helps wounds heal. A 2024 lab study made scratch wounds in fibroblasts, the cells that build connective tissue. TB-500 did not speed their closing. One of its breakdown products did (Rahaman et al., 2024).

The closest work used the full Tβ4 protein in a rodent (rat) knee ligament. The ligament was cut. Then 1 microgram of Tβ4 in a fibrin sealant, a surgical glue, was placed in the gap. At 4 weeks, treated ligaments had more evenly spaced fibre bundles and thicker collagen fibrils. Collagen is the protein that gives these tissues their strength, and fibrils are its fine strands. They also scored better on strength tests than controls (Xu et al., 2013). A rat ligament is not a human tendon, and Tβ4 is not TB-500.

A 2026 review mapped 80 studies. Most tested Tβ4, not TB-500. Tendon, ligament, muscle, cartilage and spine studies were sparse next to the wound, blood vessel, eye and bone work. It found little human evidence for these uses (McGuire et al., Applied Sciences, 2026).

The BPC-157 tendon studies we found are animal and lab work. In one rodent (rat) model, the Achilles tendon was cut from the heel bone. BPC-157 given into the belly improved healing on function, strength and tissue tests. Treated tendons also had more type I collagen (Krivic et al., 2006). In rodent (rat) tendon pieces and cells in a dish, BPC-157 sped the outgrowth of tendon cells from the tissue. It also helped the cells survive stress and increased their migration (Chang et al., 2010). Our BPC-157 tendon repair article covers that work.

Is there TB-500 dosage data beyond a few weeks?

No. With no published human studies of TB-500 at all, there is no long-term human data. FDA found no formal toxicity studies of TB-500. It found no single-dose, repeat-dose, gene damage, reproductive or cancer studies. Cycle lengths and breaks circulate online. We found no study behind any of them.

Lab and animal work on the parent protein, Tβ4, points in more than one direction. In lab tests, Tβ4 and its seven amino acid actin-binding piece both drove vessel cells to move and sprout. The two worked almost the same at about 50 nanomolar, a very low concentration (Philp et al., 2003). In a rodent (rat) kidney scarring model, Tβ4 reduced scarring and cell death (Yuan et al., 2017). In rodent (mouse) models of melanoma, a skin cancer, tumour cells making extra Tβ4 grew tumours with more blood vessels. They also spread more to the lungs (Cha et al., 2003).

None of these studies gave TB-500 to people or animals over time. FDA also says injected TB-500 may pose a significant risk of immunogenicity. That means an immune reaction to it. Our TB-500 side effects guide covers the full record.

How do you check TB-500 quality?

A certificate of analysis, or CoA, is a lab report on one batch. The public TB-500 CoA that FDA reviewed had no tests for impurities, clumps, germs or endotoxin. Endotoxin is a toxin from bacteria. FDA also found several salts and other chemical forms sold under the one name, TB-500.

See how to verify a peptide is real, how to read a peptide CoA and peptide testing labs. Our sources page sets out how UB grades vendors.